Related Experiment Videos
Systemic bevacizumab for retinal angiomatous proliferation associated with retinal pigment epithelial detachment
N Abi-Ayad1, M Mauget-Faysse, S Amara-Allieu
1Department of Ophthalmology, Croix-Rousse Hospital, Lyon, France.
Purpose:
To report the off-label use of systemic bevacizumab in a patient with stage 3 retinal angiomatous proliferation (RAP) associated with a vascularized pigmented epithelium detachment (PED).
Methods:
Interventional case report.
Results:
The patient was treated with systemic bevacizumab after obtaining fully informed consent. At 3 months post-treatment, the authors observed an improvement of one line (seven letters) in visual acuity and total regression of the PED on ocular coherence tomography. No adverse effects were observed.
Conclusions:
Systemic bevacizumab therapy appears to be safe and effective in the treatment of RAP associated with PED during this short follow-up period of 3 months. The authors recommend a large trial with long-term follow-up to confirm the promising results and evaluate the occurrence of adverse effects associated with systemic bevacizumab.
